I am beginning to understand that there can be many factors that can delay trials. However, my position is that Don should learn to under promise and then over deliver if only for the sake of his own reputation. There are very experienced scientists advising on this trial. With their experience and knowing the patient target penetration in the population and the number of clinics and the mechanics of the trial it should not be difficult to lay out a path with estimated ranges in term of best case and worse case scenarios. This should not be difficult. They should also be able to estimate setbacks within reason.

I don't think Don understands (or doesn't care about) the flippant attitude he uses in presentations has a negative impact on both brands. Potential investors sit on the sidelines because they wonder about Don's legitimacy and capabilities and should he be trusted. I have no doubt the scientists are trusted.

I've asked Sarah to ask Don for a detailed timeline chart for the mCRPC trial.

I've also asked Don to give us the status of his reverse takeover buyout of a company that will provide a TSX and/or NASDAQ listing.

We'll see.

I am still a strong believer in the science but to date neither RVX nor Zenith has any proven hits. I think we are very lucky to have your posts because you do all of the hard work to explain the science and compounds and how they work to us. RVX and Zenith fail to achieve this quality of communicatios so without you we would have very little understandable information, so thanks.

Great that the dosing has started.

Toinv